Dr. Wilson Arismendy Quezada, MD

Dr. Quezada practices at Trustees of Columbia University in the City of New York in New York, New York.

Dr. Quezada's NPI, 1295994838, was assigned on June 9, 2008. Dr. Quezada graduated from Columbia University College of Physicians and Surgeons in 2007. Dr. Quezada holds New York license 257298.

Dr. Quezada's primary practice is Trustees of Columbia University in the City of New York, at 630 W 168th St, New York, NY 10032 in New York County. The practice phone is (212) 342-5155.

Dr. Quezada's primary practice is Trustees of Columbia University in the City of New York in New York, New York. Dr. Quezada is also affiliated with NewYork-Presbyterian/Weill Cornell Medical Center. The medical group on file is ColumbiaDoctors. Dmand AI also links Dr. Quezada to 1 more hospital, named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Quezada practices, 2 sites in all. Vendor and product names are available with a free account.

Pulmonary disease is Dr. Quezada's primary specialty in the NPI Registry, under taxonomy code 207RP1001X. Dr. Quezada is licensed in New York.

Dmand AI lists asthma, bronchitis, chronic lung disease, chronic obstructive pulmonary disease (COPD), chronic respiratory failure, pleural effusion, pneumonia and pulmonary fibrosis among the conditions Dr. Quezada treats.

CMS data shows 1,502 Medicare services from Dr. Quezada across 15 procedure codes in 2024, for 715 Medicare patients. Medicare paid $107,314 for them.

CMS counts 715 Medicare patients who saw Dr. Quezada in 2024. The largest group is 65 to 74, with 290 patients. 75% of them have high blood pressure, and 75% have high cholesterol. 15% are also on Medicaid. Their average risk score is 2.08, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Quezada's median patient age at 71, with 58% women.

In 2024, Dr. Quezada wrote 1,955 Medicare Part D claims for 319 patients. 53% of them were for generic drugs. CMS names the drug for 1,663 of them, across 38 drugs with 11 or more claims each, at $565,719 in total drug cost. In 2023, CMS named 1,777 claims across 34 drugs.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 100 out of 100 for Dr. Quezada for performance year 2024, reported through an alternative payment model (APM). Dr. Quezada accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS lists Dr. Quezada as offering telehealth.

Dmand AI links 4 papers to Dr. Quezada, published from 2015 to 2024. The most frequent topics are Administration, Inhalation, Adrenal Cortex Hormones and Asthma. Dr. Quezada's most frequent co-authors are Meilan King Han, MD, Barry J. Make, MD and Byron M. Thomashow, MD.

CMS Open Payments shows 95 general payments to Dr. Quezada from 19 drug and device companies from 2016 to 2025. Food and beverage make up the largest share, 92% of the total. Boehringer Ingelheim Pharmaceuticals, Inc. paid the most, $1,096.

Dr. Quezada graduated from Columbia University College of Physicians and Surgeons in 2007.

Dr. Quezada is in network with 13 carriers, including Elevance, Excellus BlueCross BlueShield and United Healthcare. Medicare plans come from the most carriers, 9. Check the plan with the practice before a visit.